Compare · COLL vs NVO
COLL vs NVO
Side-by-side comparison of Collegium Pharmaceutical Inc. (COLL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COLL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 186.2x COLL ($1.01B).
- Over the past year, COLL is up 5.7% and NVO is down 41.7% - COLL leads by 47.4 points.
- COLL has been more active in the news (20 items in the past 4 weeks vs 11 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for COLL).
- Company
- Collegium Pharmaceutical Inc.
- Novo Nordisk A/S
- Price
- $31.06+1.82%
- $42.01-2.10%
- Market cap
- $1.01B
- $187.53B
- 1M return
- -10.21%
- -5.38%
- 1Y return
- +5.68%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 20
- 11
- Recent ratings
- 20
- 25
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest COLL
- SEC Form S-8 filed by Collegium Pharmaceutical Inc.
- SEC Form S-8 filed by Collegium Pharmaceutical Inc.
- Collegium to Participate in 2026 Jefferies Global Healthcare Conference
- Director Freund John Gordon sold $681 worth of shares (20 units at $34.05), decreasing direct ownership by 0.02% to 83,952 units (SEC Form 4)
- Director Bohlin Garen G was granted 8,741 shares, increasing direct ownership by 14% to 71,000 units (SEC Form 4)
- Director Freund John Gordon was granted 8,741 shares, exercised 8,700 shares at a strike of $16.49 and sold $142,547 worth of shares (4,127 units at $34.54), increasing direct ownership by 19% to 83,972 units (SEC Form 4)
- Director Paya Carlos V was granted 8,741 shares, increasing direct ownership by 45% to 28,323 units (SEC Form 4)
- Director Lurker Nancy was granted 8,741 shares, increasing direct ownership by 49% to 26,758 units (SEC Form 4)
- Director Balice-Gordon Rita J. was granted 8,741 shares, increasing direct ownership by 17% to 61,370 units (SEC Form 4)
- Director Glancy Donovan Michael was granted 17,482 shares (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates